Human Papillomavirus Infections and Upper Aero-Digestive Tract Cancers: The ARCAGE Study.

This is the author's manuscript

Original Citation:
Human Papillomavirus Infections and Upper Aero-Digestive Tract Cancers: The ARCAGE Study. / Anantharaman D;Gheit T;Waterboer T;Abedi-Ardekani B;Carreira C;McKay-Chopin S;Gaborieau V;Marron M;Lagiou P;Ahrens W;Holcátová I;Merletti F;Kjaerheim K;Talamini R;Simonato L;Castellsague X;Macfarlane TV;Biggs AM;Thakker N;Znaor A;Thomson P;Canova C;Conway DI;Healy CM;Tommasino M;Pawilta M;Brennan P. - In: JOURNAL OF THE NATIONAL CANCER INSTITUTE. - ISSN 0027-8874. - 105:8(2013), pp. 536-545.

Availability:
This version is available http://hdl.handle.net/2318/127712 since

Published version:
DOI:10.1093/jnci/djt053

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
This is an author version of the contribution published on:
Questa è la versione dell'autore dell’opera:

The definitive version is available at:
http://jnci.oxfordjournals.org/content/105/8/536.full
Human Papillomavirus Infections and Upper Aero-Digestive Tract Cancers: The ARCAGE Study


Affiliations of authors: Genetic Epidemiology Group (DA, BA-A, VG, PB), Infections and Cancer Biology Group (TG, SM-C, MT), and Molecular Pathology Group (CCar), International Agency for Research on Cancer, Lyon, France; Division of Genome Modifications and Carcinogenesis, German Cancer Center, Heidelberg, Germany (TW, MP); Institute of Medical Biostatistics, Epidemiology and Informatics, University of Mainz, Germany (MM); Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Athens, Greece (PL); BIPS–Institute for Epidemiology and Prevention Research, Bremen, Germany (WA); Institute for Statistics, University Bremen, Germany (WA); Charles University of Prague, 1st Faculty of Medicine, Institute of Hygiene and Epidemiology, Prague, Czech Republic (IH); Unit of Cancer Epidemiology, CERMS and University of Turin, Turin, Italy (FM); Cancer Registry of Norway, Oslo, Norway (KK); Unit of Epidemiology and Biostatistics, National Cancer Institute, IRCCS, Aviano, Italy (RT); Department of Molecular Medicine of the University of Padova, Laboratory of Public Health and Population Studies, Padova, Italy (LS, CC); Institut Català d’Oncologia, IDIBELL, CIBERESP, L’Hospitalet de Llobregat, Catalonia, Spain (XC); Warwick Medical School, University of Warwick, Coventry, UK (TVM, A-MB); School of Dentistry, University of Manchester, UK (NT); Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia (AZ); Dental School, University of Newcastle on Tyne, Newcastle, UK (PT); Dental School, University of Glasgow, Glasgow, UK (DIC); National Health Service National Services Scotland, Information Services Division, Edinburgh, UK (DIC); Trinity College School of Dental Science, Dublin, Ireland (CMH).

Correspondence to: Paul Brennan, PhD, Genetic Epidemiology Group, International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69372 Lyon CEDEX 08, France (e-mail: gep@iarc.fr).

Abstract

Background Human papillomavirus (HPV) is causally implicated in a subset of cancers of the upper aero-digestive tract (UADT).

Methods Associations between type-specific HPV antibodies were examined among 1496 UADT cancer case subjects and 1425 control subjects by estimating odds ratios (ORs) in logistic regression analyses adjusted for potential confounders. The agreement between serology and tumor markers of HPV infection, including presence of HPV DNA and p16 expression, were examined in a subset of tumors.

Results HPV16 L1 seropositivity was associated with increased risk of oral cavity and oropharyngeal cancer (OR = 1.94, 95% confidence interval [CI] = 1.03 to 3.65; OR = 8.60, 95% CI = 5.21 to 14.20, respectively). HPV16 E6 antibodies were present in 30.2% of oropharyngeal case subjects and only 0.8% of control subjects (OR = 132.0, 95% CI = 65.29 to 266.86). Combined seropositivity to HPV16 E6 and E7 was rare (n = 1 of 1425 control subjects). An agreement of 67% was observed between HPV16 E6 serology and the corresponding presence of an HPV-related cancer: four of six HPV DNA-positive/p16-overexpressing tumors were HPV16 E6 antibody positive. An HPV16 independent association was observed for HPV18 and oropharyngeal cancer...
(OR = 8.14, 95% CI = 2.21 to 29.99 for HPV18 E6 seropositivity) and HPV6 and laryngeal cancer
(OR = 3.25, 95% CI = 1.46 to 7.24 for HPV6 E7 seropositivity).

**Conclusions** These results confirm an important role for HPV16 infection in oropharyngeal cancer. HPV16 E6 antibodies are strongly associated with HPV16-related oropharyngeal cancers. Continuing efforts are needed to consider both HPV serology and p16 staining as biomarkers relevant to the etiology and natural history of HPV16-related oropharyngeal tumors. These results also support a marginal role for HPV18 in oropharyngeal cancer and HPV6 in laryngeal cancer. Cancers of the upper aero-digestive tract (UADT), comprising the oral cavity, pharynx, larynx, and esophagus, contribute to more than a million new cancer cases each year worldwide. Annually, more than 700,000 people die of the disease (1). Tobacco and alcohol are known risk factors, and human papillomavirus (HPV) infection has been implicated in a subset of UADT cancers (2,3). The high-risk types, HPV16 and HPV18, are the commonly identified HPV types (>90% of HPV-positive tumors), consistent with observations in cervical and other ano-genital cancers (4–6). However, unlike in cervical cancer, not all HPV infections in UADT cancer are transcriptionally active (7).

The epidemiological, molecular, and mechanistic association of HPV16 and UADT cancer is strongest for the oropharynx (8–12). Even so, large variation in HPV16 DNA prevalence (8%–100%) is observed, possibly because of differences in study population, composition of tumor subsite, proportion of other known risk factors including smoking and alcohol, type of specimen assayed, and assay variability (5,13). Conversely, HPV18 appears to be rare in oropharyngeal cancers (5). Recently developed serological methods simultaneously detect type-specific antibodies to multiple HPV proteins, including early viral oncoproteins E6 and E7 that are considered markers of ongoing HPV-related malignancy. The studies published so far have consistently reported an association between presence of HPV16 antibodies and risk of oropharyngeal cancer (4,8,14–16). Even so, the usefulness of serological markers in identifying an HPV-related cancer is poorly understood. Further, the contribution of HPV infections to nonoropharyngeal sites and, particularly, of other mucosal HPV types remains unclear.

Using a large panel of markers of HPV infection in a large case–control study, we aimed to: 1) comprehensively evaluate the association between serological markers of oncogenic HPV infection and UADT cancer, 2) estimate how this varies by subsite, 3) examine the important serological associations in a subset of tumor biopsies, and 4) clarify the true proportion of HPV16-related UADT cancer by anatomic site.

**Methods**

**Study Population**

One thousand four hundred ninety-six case subjects and 1425 control subjects with an available plasma sample from the Alcohol-Related Cancers and Genetic Susceptibility in Europe (ARCAGE) study were included in this study. Details of the study have been described previously (17). Briefly, 2304 case subjects and 2227 control subjects were recruited from 10 European countries during the period from 2002 to 2005 using a standardized protocol in all centers (except France). Case subjects had histologically or cytologically confirmed primary cancers of the oral cavity (International Classification of Diseases for Oncology [ICD-O] C00.3–C00.9, C02.0–C06.9, excluding C02.4, C02.8, C02.9, C05.1, C05.2, C05.8, C05.9), oropharynx (ICD-O: C01, C02.4, C05.1–C05.2, C09, C10), hypopharynx and larynx (ICD-O: C13, C32), esophagus (ICD-O: C15), and nonspecified and overlapping sites (ICD-O: C02.8, C02.9, C05.8, C05.9, C14.0, C14.8, C32.8). Cancer stage was ascertained based on the sixth edition of the staging atlas developed by the American Joint Committee on Cancer (AJCC). A comparable group of hospital- or population-based controls were recruited in each center and frequency matched for age, sex, and area of residence. All subjects underwent personal interviews to record lifestyle exposures; details are described elsewhere (17). Briefly, tobacco use was broadly categorized as ever or never smokers; ever smokers were defined as individuals who smoked any tobacco product at least once a week for a year. Ever drinkers were
those who reported ever consumption of any alcoholic beverage. The consumption of all types of alcoholic beverages were estimated, and the total frequency was expressed in terms of drinks of alcohol per day based on the definition that one drink equivalent was 14 grams, 18mL, or 0.49 ounces of alcohol (18). Informed consent was obtained from all participants in the study, and the study was approved by the ethical review boards at the participating centers and by the International Agency for Research on Cancer Ethical Review Committee.

Laboratory Methods

Serological Methods.

Plasma samples from 1496 case subjects and 1425 control subjects were tested for type-specific HPV antibodies using bead-based multiplex serology method, as described elsewhere (19). We report associations on 27 markers of mucosal HPV infection, including high-risk types—HPV16 (L1, E1, E2, E4, E6, E7), HPV18 (L1, E6, E7), HPV31 (L1, E6, E7), HPV33 (L1, E6, E7), HPV45 (L1, E6, E7), and HPV52 (L1, E6, E7)—and low-risk types—HPV6 (L1, E6, E7) and HPV11 (L1, E6, E7). Additionally, we tested antibodies to cutaneous HPV types (HPV1, HPV5, HPV8, and HPV38) and non-HPV-related antibodies (P53, P16, JCV, HHV, and EBV) as specificity controls. Serology data were generated as continuous measures of mean fluorescence intensity, which were dichotomized using cutoffs derived from earlier studies (20,21). Briefly, a bridging panel that included a reference set of sera from two previous studies of approximately 2000 Germans and 370 Korean students who tested negative for genital DNA of 25 HPV types and were self-declared as sexually naive was used to define seropositivity thresholds. Data normalization was performed using the ratio of predefined and extrapolated cutoffs, and seropositivity was set at mean plus three standard deviations.

Tumor Tissue Analyses.

One hundred fifty snap-frozen tumor tissues were identified that included 125 cases with a high a priori expectation for HPV infection based on serology (all HPV16 L1, E6, and E7 positives), tumor site (all cancers of the oropharynx and overlapping sites), and other characteristics (all women, young male never smokers) and 25 cases with a low a priori expectation, which included cancers of the oral cavity or larynx among male smokers. Based on pathological evaluation that aimed to confirm tumor histology and record cellular features, 30 tumors were excluded because of insufficient tumor tissue, absence of tumor tissue (only fibroconnective tissue, necrotic tissue, etc), unknown histology, or unknown tumor origin. The p16 expression was qualitatively evaluated using the ClINtec Histology P16INK4a Kit (9511, mtmlabs, Heidelberg, Germany) following manufacturer’s instructions. Expression was scored based on the percentage and intensity of nuclear or cytoplasmic staining. A combined score of four or greater was considered positive for p16INK4a overexpression (22). When this algorithm was subsequently compared with simpler p16 scoring methods used in other head and neck cancer studies (7,23,24), identical results were obtained. DNA extraction from biopsies was performed using the Qiagen BioRobot EZ1 (Qiagen, Hilden, Germany). HPV genotyping using the type-specific E7 polymerase chain reaction bead-based multiplex assay (TS-E7-MPG, IARC, Lyon, France) was performed to detect all high-risk HPV types (HPV16, -18, -26, -31, -33, -35, -39, -45, -51, -52, -53, -56, -58, -59, -66, -68a, -68b, -73, and -82) and three low-risk HPV types (HPV6, -11, and -70) (25–27). Briefly, the reporter fluorescence was quantified using Luminex reader 200 (Luminex Corporation, Austin, TX), and cutoffs were computed by adding 5 to 1.1 multiplied by the median background value expressed as median fluorescence intensity.

Statistical Analysis

The association between serological markers of HPV infection and UADT cancer was examined by calculating the odds ratios (ORs) and corresponding 95% confidence intervals (CIs) using unconditional logistic regression models adjusted for age, sex, level of education (finished primary...
school, finished secondary school, or university degree), pack years of tobacco smoking (never, <20, 20–39, 40–59, 60–79, and ≥80), number of alcoholic drinks consumed per day (never, <1, 1–2, 3–4, 5–6, ≥7), and country.

The HPV types included in this analysis fall into three main species: alpha7 (HPV18 and HPV45), alpha9 (HPV16, HPV31, HPV33, and HPV52), and alpha10 (HPV6 and HPV11). Within these, it is possible that a positive infection from one type may result in seropositivity for another type because of cross-reactivity. To account for this, we performed antigen-specific sensitivity analysis. The association between HPV type-specific antibodies and UADT cancer were reexamined after exclusion of subjects who were seropositive for more than one homologous protein.

Multiple methods have been proposed to identify HPV-related head and neck cancers, including p16 immunohistochemistry, HPV DNA detection (by in situ hybridization or other polymerase chain reaction–based methods), and RNA expression of E6 and E7 genes (28–30). Although RNA expression is likely to represent the closest to a gold standard, it requires appropriate collection of fresh tumor tissue that preserves RNA integrity. Given that we did not collect RNA from tumor tissue, we adopted an alternate algorithm that included HPV DNA detection and p16 overexpression (7). Based on this algorithm, we classified tumors into HPV16 DNA-positive/p16-overexpressing (referred to as HPV-related), HPV16 DNA-positive/p16-negative, and HPV16 DNA-negative tumors. This algorithm was initially developed by comparing different methods for HPV detection among 48 oral and oropharyngeal cancers, and we are assuming it is also relevant for laryngeal cancers. We subsequently assessed the agreement between serological and tumor markers of HPV16 infection based on this algorithm. All statistical analyses were performed using STATA statistical software, version 11 (StataCorp, College Station, TX), and all reported P values are two sided. Statistical significance was set at P less than .05.

Results

Table 1 shows the characteristics of the study population. The analysis included 1496 case subjects and 1425 control subjects in the original study with an available plasma sample. The serology subset was comparable with the overall study on all the demographic and lifestyle factors (data not shown). Of the 1496 case subjects, 24% were diagnosed with oral cavity cancer, 22% were diagnosed with oropharyngeal cancer (123 were tonsillar), 35% were diagnosed with laryngeal/hypopharyngeal cancers, and 13% were diagnosed with esophageal cancer. Compared with control subjects, case subjects attained lower levels of education and were more often smokers. As expected, smoking and alcohol consumption were strong risk factors for UADT cancer. A clear dose–response relationship was observed between increasing pack years of smoking, number of alcoholic drinks consumed per day, and the risk of UADT cancer overall and for each subsite (data not shown). Cancer stage was ascertained for 81% of case subjects. The proportion of subjects missing stage information was not associated with any of the patient characteristics or exposures, including age, sex, smoking status, alcohol consumption, or the presence of HPV antibodies.

<table>
<thead>
<tr>
<th>Description</th>
<th>Control subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 1425)</td>
<td>(n = 1496)</td>
<td>(n = 120)</td>
</tr>
<tr>
<td>Country</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Czech Republic</td>
<td>185 (13)</td>
<td>187 (12)</td>
<td>16 (13)</td>
</tr>
<tr>
<td>Germany</td>
<td>187 (13)</td>
<td>188 (13)</td>
<td>—</td>
</tr>
<tr>
<td>Greece</td>
<td>167 (12)</td>
<td>224 (15)</td>
<td>53 (44)</td>
</tr>
<tr>
<td>Italy</td>
<td>462 (32)</td>
<td>440 (29)</td>
<td>51 (43)</td>
</tr>
<tr>
<td>Ireland</td>
<td>16 (1)</td>
<td>33 (2)</td>
<td>—</td>
</tr>
<tr>
<td>Norway</td>
<td>168 (12)</td>
<td>162 (11)</td>
<td>—</td>
</tr>
</tbody>
</table>
### Serological series

<table>
<thead>
<tr>
<th>Description</th>
<th>Control subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 1425)</td>
<td>(n = 1496)</td>
<td>(n = 120)</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>112 (8)</td>
<td>119 (8)</td>
<td>—</td>
</tr>
<tr>
<td>Spain</td>
<td>82 (6)</td>
<td>89 (6)</td>
<td>—</td>
</tr>
<tr>
<td>Croatia</td>
<td>46 (3)</td>
<td>54 (4)</td>
<td>—</td>
</tr>
</tbody>
</table>

#### Age group, years

<table>
<thead>
<tr>
<th></th>
<th>Control subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤55</td>
<td>494 (35)</td>
<td>498 (32)</td>
<td>38 (32)</td>
</tr>
<tr>
<td>56–65</td>
<td>456 (32)</td>
<td>551 (37)</td>
<td>39 (33)</td>
</tr>
<tr>
<td>≥66</td>
<td>475 (33)</td>
<td>447 (30)</td>
<td>43 (36)</td>
</tr>
</tbody>
</table>

#### Sex

<table>
<thead>
<tr>
<th></th>
<th>Control subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men</td>
<td>1059 (74)</td>
<td>1190 (80)</td>
<td>81 (68)</td>
</tr>
<tr>
<td>Women</td>
<td>366 (26)</td>
<td>306 (20)</td>
<td>39 (32)</td>
</tr>
</tbody>
</table>

#### Smoking status

<table>
<thead>
<tr>
<th></th>
<th>Control subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Never</td>
<td>516 (36)</td>
<td>172 (12)</td>
<td>32 (27)</td>
</tr>
<tr>
<td>Former</td>
<td>475 (33)</td>
<td>361 (24)</td>
<td>16 (13)</td>
</tr>
<tr>
<td>Current</td>
<td>434 (31)</td>
<td>963 (64)</td>
<td>72 (60)</td>
</tr>
</tbody>
</table>

#### Alcohol consumption*

<table>
<thead>
<tr>
<th></th>
<th>Control subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Never</td>
<td>172 (12)</td>
<td>89 (6)</td>
<td>8 (6)</td>
</tr>
<tr>
<td>Former</td>
<td>134 (9)</td>
<td>206 (14)</td>
<td>18 (15)</td>
</tr>
<tr>
<td>Current</td>
<td>1118 (79)</td>
<td>1201 (80)</td>
<td>94 (78)</td>
</tr>
</tbody>
</table>

#### Level of education attained*

<table>
<thead>
<tr>
<th></th>
<th>Control subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finished primary</td>
<td>444 (31)</td>
<td>630 (42)</td>
<td>70 (58)</td>
</tr>
<tr>
<td>Finished secondary</td>
<td>834 (59)</td>
<td>798 (53)</td>
<td>40 (33)</td>
</tr>
<tr>
<td>University degree</td>
<td>147 (10)</td>
<td>66 (4)</td>
<td>10 (8)</td>
</tr>
</tbody>
</table>

#### Cancer site

<table>
<thead>
<tr>
<th></th>
<th>Control subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral cavity</td>
<td>366 (24)</td>
<td>42 (35)</td>
<td>42 (35)</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>324 (22)</td>
<td>36 (30)</td>
<td>36 (30)</td>
</tr>
<tr>
<td>Hypopharynx/larynx</td>
<td>529 (35)</td>
<td>16 (13)</td>
<td>16 (13)</td>
</tr>
<tr>
<td>Esophagus</td>
<td>200 (13)</td>
<td>8 (7)</td>
<td>8 (7)</td>
</tr>
<tr>
<td>Overlapping†</td>
<td>77 (5)</td>
<td>18 (15)</td>
<td>18 (15)</td>
</tr>
</tbody>
</table>

#### Stage*

<table>
<thead>
<tr>
<th></th>
<th>Control subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
<th>Case subjects, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I and II</td>
<td>530 (35)</td>
<td>48 (40)</td>
<td>48 (40)</td>
</tr>
<tr>
<td>III and IV</td>
<td>686 (46)</td>
<td>67 (56)</td>
<td>67 (56)</td>
</tr>
</tbody>
</table>

---

* Numbers do not add up to the total because of missing data: information on alcohol consumption was missing for one control subject, education level data was missing for two case subjects, and stage was missing for 280 case subjects.

† Includes cancers of overlapping topologies and nonspecified cancers of the head and neck.

### HPV16 Antibodies and UADT Cancer

#### Table 2.

Human papillomavirus 16 (HPV16) antibodies and oropharyngeal cancer risk

| HPV16 antibody | Control subjects (n = 1395) | Oropharynx cancer (n = 321) | OR (95% CI) |
|               | Seropositive, No. (%)† | Seropositive, No. (%)† |                  |
| L1            | 36 (2.6)             | 44 (13.7)             | 8.60 (5.21 to 14.20) |
| E1            | 31 (2.2)             | 69 (21.2)             | 22.63 (13.63 to 37.57) |
| E2            | 29 (2.1)             | 81 (25.2)             | 30.65 (18.56 to 50.64) |
| E4            | 85 (5.9)             | 41 (12.7)             | 2.59 (1.68 to 4.00)  |
Table 3.
Human papillomavirus (HPV) type-specific antibodies and oropharyngeal cancer risk

<table>
<thead>
<tr>
<th>HPV antibody</th>
<th>Control subjects (n = 1395)*</th>
<th>Oropharynx cancer (n = 321)* OR (95% CI)†</th>
<th>Control subjects (n = 1288)</th>
<th>Oropharynx cancer (n = 198) OR (95% CI)‡</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Seropositive, No. (%)‡</td>
<td></td>
<td>Seropositive, No. (%)‡</td>
<td></td>
</tr>
<tr>
<td>L1</td>
<td>50 (3.6)</td>
<td>21 (6.5)</td>
<td>32 (2.3)</td>
<td>9 (4.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.32 (1.33 to 4.04)</td>
<td>2.37 (1.06 to 5.32)</td>
<td></td>
</tr>
<tr>
<td>E6</td>
<td>7 (0.5)</td>
<td>11 (3.4)</td>
<td>6 (0.4)</td>
<td>7 (3.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8.16 (2.81 to 23.66)</td>
<td>8.14 (2.21 to 29.99)</td>
<td></td>
</tr>
<tr>
<td>E7</td>
<td>5 (0.4)</td>
<td>8 (2.5)</td>
<td>3 (0.2)</td>
<td>2 (1.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9.31 (2.75 to 31.50)</td>
<td>4.81 (0.65 to 35.45)</td>
<td></td>
</tr>
<tr>
<td>HPV31</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L1</td>
<td>51 (3.7)</td>
<td>16 (5.0)</td>
<td>38 (2.7)</td>
<td>3 (1.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.90 (1.03 to 3.51)</td>
<td>0.92 (0.27 to 3.12)</td>
<td></td>
</tr>
<tr>
<td>E6</td>
<td>17 (1.2)</td>
<td>7 (2.2)</td>
<td>16 (1.1)</td>
<td>2 (1.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.71 (0.66 to 4.41)</td>
<td>0.67 (0.14 to 3.28)</td>
<td></td>
</tr>
<tr>
<td>E7</td>
<td>14 (1.0)</td>
<td>53 (16.5)</td>
<td>10 (0.7)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>32.33 (16.93 to 61.74)</td>
<td>0.77 (0.09 to 6.57)</td>
<td></td>
</tr>
<tr>
<td>HPV33</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L1</td>
<td>37 (2.7)</td>
<td>19 (5.9)</td>
<td>26 (1.9)</td>
<td>8 (4.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.73 (1.46 to 5.09)</td>
<td>1.97 (0.78 to 4.96)</td>
<td></td>
</tr>
<tr>
<td>E6</td>
<td>7 (0.5)</td>
<td>14 (4.4)</td>
<td>4 (0.3)</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12.95 (4.90 to 34.28)</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>E7</td>
<td>21 (1.5)</td>
<td>62 (19.3)</td>
<td>15 (1.1)</td>
<td>2 (1.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>26.48 (15.18 to 46.20)</td>
<td>0.62 (0.11 to 3.56)</td>
<td></td>
</tr>
<tr>
<td>HPV45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L1</td>
<td>41 (2.9)</td>
<td>15 (4.7)</td>
<td>29 (2.1)</td>
<td>5 (2.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.89 (0.99 to 3.61)</td>
<td>1.19 (0.42 to 3.40)</td>
<td></td>
</tr>
<tr>
<td>E6</td>
<td>11 (0.8)</td>
<td>7 (2.2)</td>
<td>10 (0.7)</td>
<td>2 (1.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3.50 (1.28 to 9.57)</td>
<td>1.79 (0.32 to 9.86)</td>
<td></td>
</tr>
<tr>
<td>E7</td>
<td>10 (0.7)</td>
<td>6 (1.9)</td>
<td>10 (0.7)</td>
<td>2 (1.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4.29 (1.47 to 12.50)</td>
<td>2.55 (0.53 to 12.27)</td>
<td></td>
</tr>
</tbody>
</table>

* Thirty control subjects and three oropharyngeal case subjects were missing data on smoking pack years or frequency of alcohol consumption.
† Represents seropositivity to the corresponding HPV16 antigen.
‡ Odds ratios (ORs) were adjusted for age, sex, level of education, smoking pack years, and number of alcoholic drinks consumed per day; corresponding seronegative group was considered as reference. CI = confidence interval.

Non-HPV16 Antibodies and UADT Cancer
Antibodies to high-risk types HPV18 (L1, E6, and E7), HPV31 (L1 and E7), HPV33 (L1, E6, and E7), HPV45 (L1, E6, and E7), and HPV52 (L1 and E7) and low-risk type HPV11 L1 were associated with oropharyngeal cancer (Table 3). To test for an HPV16-independent association, if any, we excluded all HPV16 L1, E6, and E7 seropositives. Although the HPV11 L1 association was consistent, only the associations between HPV18 L1 and E6 remained robust (OR = 2.37, 95% CI = 1.06 to 5.32; and OR = 8.14, 95% CI = 2.21 to 29.99, respectively). We found associations for HPV6 (L1 and E7) and UADT cancer that appeared to be driven by laryngeal cancer. An HPV16-independent effect was observed for HPV6 E7 and laryngeal cancer (OR = 3.25, 95% CI = 1.46 to 7.24, Supplementary Table 3, available online). No associations were observed between seropositivity to cutaneous HPV types and UADT cancer (data not shown).
Control subjects \((n = 1395)^{*}\) | Oropharynx cancer \((n = 1288)\) | Control subjects \((n = 198)\) | Oropharynx cancer \((n = 198)\)
---|---|---|---
**HPV antibody** | **Seropositive, No. (%)** | **OR (95% CI)** | **Seropositive, No. (%)** | **OR (95% CI)**
---|---|---|---|---
HPV52 | | | | |
L1 | 33 (2.4) | 15 (4.7) | 2.81 (1.43 to 5.50) | 20 (1.4) | 4 (2.0) | 1.94 (0.61 to 6.20)
E6 | 11 (0.8) | 4 (1.2) | 1.48 (0.41 to 5.31) | 10 (0.7) | — | —
E7 | 25 (1.8) | 28 (8.7) | 7.79 (4.27 to 14.19) | 20 (1.4) | 4 (2.0) | 2.11 (0.65 to 6.82)

**Antibodies to mucosal low-risk HPV types**
HPV6 | | | | |
L1 | 223 (16.0) | 65 (20.2) | 1.17 (0.84 to 1.63) | 187 (13.4) | 46 (23.2) | 1.53 (1.02 to 2.30)
E6 | 10 (0.7) | 1 (0.3) | 0.36 (0.04 to 2.95) | 9 (0.6) | — | —
E7 | 18 (1.3) | 5 (1.6) | 1.10 (0.38 to 3.22) | 16 (1.1) | 3 (1.5) | 1.35 (0.34 to 5.39)
---|---|---|---|---|---|---
HPV11 | | | | |
L1 | 72 (5.2) | 30 (9.3) | 1.85 (1.15 to 2.98) | 22 (1.6) | 2 (1.0) | 1.83 (0.96 to 3.48)
E6 | 22 (1.6) | 2 (0.6) | 0.36 (0.08 to 1.71) | 11 (0.8) | 1 (0.5) | 0.53 (0.10 to 2.86)
E7 | 12 (0.9) | 4 (1.2) | 1.33 (0.37 to 4.83) | 198 (14.2) | 25 (12.6) | 0.29 (0.02 to 3.40)

* Thirty control subjects and three oropharyngeal case subjects were missing data on smoking pack years or frequency of alcohol consumption.
† Represents corresponding HPV type-specific seropositivity.
‡ Odds ratios (ORs) were adjusted for age, sex, level of education, smoking pack years, and number of alcoholic drinks consumed per day; corresponding seronegative group was considered the reference. CI = confidence interval.

**Sensitivity Analysis**
The observed results were insensitive to varying definitions of seropositivity, either as continuous data or after doubling of calculated thresholds (data not shown). This could be because of the high HPV16 antibody titers among oropharyngeal case subjects. The antibody titers for the majority of the HPV16 E6 seropositive control subjects \((n = 11)\) and nonoropharyngeal case subjects \((n = 21)\), on the other hand, were just above the cutoff. For example, upon doubling of the seropositivity threshold for HPV16 E6, although there was a marginal decrease in the proportion of seropositive control subjects (from 0.8% to 0.5%), the proportion of positive oropharyngeal cancer did not vary (30.2% to 29.6%). Consistently, the effect estimate remained robust \((OR = 190.9, 95\% CI = 82.85 to 440.0)\). Further, the important associations, including those of HPV16, HPV18, and HPV6, did not change substantially upon exclusion of phylogenetically related, homologous, and potentially cross-reacting proteins (Supplementary Table 4, available online).

**Tumor Tissue Analysis**
Because HPV16 antibodies formed the principal associations observed in this study and the results appeared to be driven by the oropharyngeal cancer, we prioritized a subset of 120 tumors for HPV genotyping and p16 expression to examine the agreement between HPV serology and cellular markers of HPV infection in the corresponding tumor. These included all HPV16 seropositives and all available oropharyngeal tumors. We identified 47 tumors that were positive for any HPV DNA (39.2%). Of these, 44 were positive for HPV16 (93.6%), two were positive for HPV31 (4.2%), six were positive for HPV33 (12.8%), two were positive for HPV35 positive (4.2%), and one was positive for low-risk HPV66 (2.1%) (Figure 2). Eight multiple infections involving HPV16 were identified, two involving HPV31 and six involving HPV33. Three non-HPV16-positive tumors were identified (two for HPV35 and one for HPV66). The largest proportion of HPV16 positives
were observed for oropharynx, followed by oral cavity, larynx, esophagus, and overlapping topologies (43%, 32%, 11%, 7%, and 7%, respectively; data not shown). An algorithm for detecting HPV-related head and neck cancer has been proposed that includes an initial test for p16 overexpression followed by HPV DNA detection. Only cases positive at both stages were judged to have an HPV-related tumor (7). In all, nine tumors overexpressed the p16 protein: seven were cancers of the oropharynx, one was a cancer of the larynx, and one was a cancer of the esophagus. Of the nine p16-positive tumors, six were concurrently positive for HPV16 DNA, indicative of an HPV-related tumor; all six were oropharyngeal cancers. Thirty-seven tumors were negative for p16 but positive for HPV DNA. Based on serology, ten of the 120 tumors tested were HPV16 E6 positive (all oropharyngeal case subjects), of which four were positive for HPV16 DNA and overexpressed p16 protein, three were HPV16 DNA-positive/p16-negative tumors, and three were negative for both HPV16 DNA and p16 (Figure 3). We observed a 67% agreement between HPV16 E6 serology and tumor measures of HPV infection, although it is important to mention that these results were based on small numbers. Seropositivity was observed in four of six HPV16 DNA-positive/p16-positive tumors (Figure 3; Supplementary Table 5, available online). Based on serology, 30.2% of oropharyngeal cancers were positive for antibodies to HPV16 E6. Based on HPV16 DNA presence and p16 overexpression, the HPV16-related fraction was 17% at the oropharynx; none of the cancers at other sites of UADT appeared to be HPV related (Table 4).

Table 4.

<table>
<thead>
<tr>
<th>Cancer site</th>
<th>HPV16 related E6 serology*</th>
<th>Tumor markers†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive/total, No. (%)</td>
<td>Positive/total, No. (%)</td>
</tr>
<tr>
<td>UADT cancer</td>
<td>119/1496 (8.0)</td>
<td>6/120 (5)</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>98/324 (30.2)</td>
<td>6/36 (17)</td>
</tr>
<tr>
<td>Oral cavity</td>
<td>4/366 (1.1)</td>
<td>0/42</td>
</tr>
<tr>
<td>Larynx‡</td>
<td>8/529 (1.5)</td>
<td>0/16</td>
</tr>
<tr>
<td>Esophagus</td>
<td>5/200 (2.6)</td>
<td>0/8</td>
</tr>
</tbody>
</table>

* Proportion of case subjects in each category positive for HPV16 E6 antibodies.
† Indicates HPV16 DNA-positive and p16-overexpressing tumors by total tumors in each category.
‡ Includes larynx and hypopharynx case subjects.

Discussion

In this large case–control study, we examined the associations between 27 serological markers of mucosal HPV infection and the risk of UADT cancer. Among the various HPV types assessed, strong associations were observed between HPV16 antibodies and oropharyngeal cancer. The agreement between HPV16 E6 seropositivity and tumor markers of HPV infection was 67% in this series (four of six HPV DNA-positive/p16-overexpressing tumors were HPV16 E6 antibody positive). Additionally, we found associations for HPV18 antibodies and oropharyngeal cancer and HPV6 and laryngeal cancer. HPV16 L1 antibodies are considered markers of previous exposure (31,32). In interpreting the association between L1 antibodies and cancer, it is important to note that capsid seropositivity represents a mixed group of current and past infections in a subset of individuals who seroconvert. It is interesting that even so, such antibodies are consistently associated with oropharyngeal cancer (4,8,15,16). It can be argued that the presence of capsid antibodies may reflect systemic exposure from any mucosal HPV infection. This would appear unlikely given we observed consistent associations across sex and included first primary cancers of the UADT. Higher risk estimates
among never smokers support the notion that HPV16 E6 antibody-positive and smoking-related cancers of the UADT follow distinct etiologies (9). HPV16 E6 and E7 antibodies are regarded markers of current HPV-related malignancy, and low E6 and E7 antibody prevalence in the general control population in previous studies support this view (4,8,15,16). Consistently, HPV16 E6 seroprevalence was rare (0.8%) in this study, whereas HPV16 E7 was more common (4.6%), possibly because of assay limitations. HPV16 E6-seropositive UADT case subjects were more likely to be men, never smokers, and light drinkers (data not shown), consistent with the previously described risk profile (9). Contrarily, antibodies to E1, E2, and E4 are less well understood. E1 and E2 proteins are expressed in episomal viral infection and often disrupted during viral integration into the host genome (33). In this study, such antibodies were associated with oropharyngeal cancer risk. These results confirm findings from a previous study involving 40 oropharynx cancers and 50 cancer-free control subjects (34). This analysis included both squamous and nonsquamous histologies. Because these cancers are likely to vary based on etiology, stratified analyses were performed. Although the non-HPV16 associations were principally driven by squamous cell cancers, presence of HPV16 antibodies were associated with increased risk of both squamous and nonsquamous oropharyngeal cancer (Supplementary Table 6, available online). It is important to note that the number of nonsquamous oropharyngeal cancer case subjects were limited (n = 22). Although the presence of an undiagnosed current or prior cervical neoplasia among the female oropharyngeal case subjects cannot be ruled out, this is unlikely to explain the strong associations observed in this study. Future studies that determine HPV status in cervico-vaginal samples are warranted.

Several studies have examined the association between HPV16 and esophageal cancer; however the results have been inconsistent (35,36). We observed inconsistent associations based on HPV16 serology (data not shown). Even though three tumors were HPV16 DNA positive, p16 overexpression was not observed, possibly indicating inactive infections. Hence, we conclude that although HPV16 infections are common (37.5%), any contribution to esophageal squamous carcinoma is unlikely. The observed site-specific differences in the association of HPV16 markers could reflect differences in viral load, viral states (episomal or integrated), site-specific immune differences, or true noncausal associations. Even though HPV16 DNA was observed in nonoropharyngeal sites of UADT, none of the tumors overexpressed p16 protein. Further, among HPV16 DNA-positive tumors, the proportion of HPV16E seropositivity (E1, E2, E4, E6, and E7) was lower for nonoropharyngeal cancers than for cancers of the oropharynx, although the proportion of L1 seropositivity did not differ, indicating that, although infection rates at heterogeneous UADT sites are likely to be similar, HPV16-related cancer rates are lower for nonoropharyngeal sites. These conclusions are supported by serological associations for HPV16 that appear to principally driven by oropharyngeal cancer.

Among other mucosal HPV antibodies examined, we observed strong associations for HPV18, particularly L1 and E6 antibodies, and oropharyngeal cancer risk that were robust upon several sensitivity analyses. Because HPV18 DNA was not identified and the seropositive oropharyngeal cancer fraction was small (7%), we conclude that the contribution of HPV18 to oropharyngeal cancer is likely to be marginal. We did not observe an HPV16-independent association for HPV31, HPV33, HPV45, and HPV52 antibodies and oropharyngeal cancer. We did not identify any HPV45 or HPV52 DNA. Given the low seroprevalence of these markers (1% for HPV45 E6, and E7 and 2% for HPV52), the contribution of these types to oropharyngeal cancer, at least in Europe, is likely to be small. It is possible that these types may be more important in other populations with higher infection prevalence, such as observed for HPV52 among Asian women (31). Serological analysis indicated a sevenfold increased risk of UADT cancer with HPV31 E7, albeit in the presence of HPV16. This is supported by tumor analyses where we found that both of the HPV31 DNA-positive tumors were concomitantly HPV16 positive. Even so, the correlation between HPV31 E7 serology and HPV31 positive tumor was moderate (50%; data not shown). Similarly, all six HPV33 DNA-positive tumors were concurrently positive for HPV16 as indicated by serology. Again, the type-
specific correlation of HPV33 E6 and E7 antibodies and HPV33 DNA was poor (17% and 29%, respectively). Given that serology supports a role of 5% of HPV31 and almost 6% of HPV33 in oropharyngeal cancer, the contribution of these types warrants further investigation. The causal association, if any, will be difficult to disentangle given the concurrence with HPV16. Low-risk mucosal HPV types such as HPV6 and HPV11 are associated with benign laryngeal papillomas, a rare disease that occasionally undergoes malignant transformation (37). In this study, HPV6 L1 and E7 were associated with laryngeal cancer independent of HPV16 serology. The proportion of HPV6-related cancers (E6 laryngeal seropositivity = 3.5%), although small, is consistent with previous estimates, indicating larger focused studies with detailed tumor analyses will be required to clarify the rare causal contribution of HPV6 to laryngeal cancer. It is important to mention that the tumor subset was prioritized to examine the serological associations of HPV16 and oropharyngeal cancer and the results for non-HPV16 types and nonoropharyngeal cancer sites should be interpreted with caution.

In this study, nearly 94% of all HPV-positive tumors were positive for HPV16 DNA, consistent with earlier reports (4,10,38,39). Other types found were HPV31, HVP33, HPV35, and HPV66, together contributing a total of 23%, higher than previous estimates (5,13). Presence of HPV16 DNA, although necessary, is not sufficient to establish causality because it includes a subset of transient infections. In this study, we found 37 HPV DNA-positive/p16-negative tumors, indicating that the majority of HPV16 infections (84%) may be inactive. Interestingly, more than 60% of these were smokers (all oropharyngeal case subjects), suggestive of a smoking-related etiology. Viral transcription and the production of viral oncoprotein E7 leads to the upregulation of p16 by the retinoblastoma pathway (33). A previous study found 100% sensitivity for p16 as a surrogate marker to identify HPV16-related cancers of the head and neck (7). It can be argued that HPV-independent mechanisms could result in the upregulation of p16. We found three p16-positive and HPV16 DNA-negative tumors (2.5%), lower than the previous estimates (13). It is also plausible that infection by non-HPV16 types could upregulate p16. In this study, we did not observe p16 overexpression among any of the HPV16-negative tumors, although three of the six HPV16-related tumors were concomitantly positive for HPV31 or HPV33. Although HPV16 DNA-positive/p16-negative tumors have been described as HPV-unrelated tumors, the true etiological involvement of HPV remains to be demonstrated. Future studies testing multiple markers of HPV activity will be required to address this. Based on serology, we found that nearly 30% of oropharyngeal cancers were HPV16 E6 positive. These results are highly consistent with the recent report on the global burden of cancer attributable to infections, where the estimated HPV-related oropharyngeal cancer fraction in Europe was between 17% and 39% (40). HPV16 E6 serology identified 67% of HPV-related cancers (four of six HPV16 DNA-positive/p16-overexpressing tumors), higher than previously published, possibly because of higher seropositivity thresholds (7). Inclusion of HPV16 E2 or E4 markers further increased the detection from 67% to 83%, warranting further investigation on the panel of serological markers that can accurately identify HPV-driven cancers. In light of the high specificity of HPV16 E6 (0.1% among controls), the strong oropharyngeal-specific association observed in this study, and the promising sensitivity to identify HPV-related oropharyngeal cancer (though based on small numbers; 4 of 6 HPV16 DNA-positive/p16-overexpressing tumors of 120 tumors tested), and based on additional data from other groups indicating improved prognosis among HPV16 E6 antibody-positive case subjects (41,42), further studies are needed to evaluate HPV16 serology as a biomarker for HPV16-related oropharyngeal cancer.

Our study has several limitations. First, the reported significance levels were not adjusted for multiple testing. However, even under the assumption of complete independence, important associations (particularly HPV16, HPV18, and HPV6) were robust. Second, reverse causality is a concern in the interpretation of these results given that blood samples were drawn at diagnosis. However, our results are concordant with the prospective case–control study that found twofold increased head and neck cancer risk with HPV16 capsid seropositivity (43). Third, we restricted our analyses to the alpha papillomavirus family; although this could potentially underestimate the role
of HPV in UADT cancer, literature indicates that these constitute known carcinogenic types. Our study has several strengths. The study was large enough to allow examination of site-specific associations of HPV infection. The results of the sero-epidemiologic study were examined in a tumor subset that reflected an agreement of 67% between serology and presence of a HPV16-related tumor (four of six HPV DNA-positive/p16-overexpressing tumors were HPV16 E6 antibody positive). Additionally, our results were robust upon various sensitivity analyses. In conclusion, the majority of the HPV16 infections in the UADT appear to be inactive. HPV16 E6 antibodies are promising markers to identify HPV16 DNA-positive/p16-overexpressing tumors, indicating that at least 30% of oropharyngeal cancers are HPV16 related. Larger focused studies will be required to clarify the appropriate algorithm to accurately identify HPV-related UADT cancers. Given the increasing proportion of oropharyngeal cancers in Europe, the value of HPV16 E6 serology warrants further investigation. It will be important to determine when in the course of a malignancy antibodies to HPV16 E6 develop. Do such antibodies precede a clinically diagnosable disease? Large cohort studies will be required to address some of these questions.

**Funding**
The ARCADE study was supported by the grant from European Commission’s 5th Framework Program (contract QLKI-2001-00182). This project was partly funded by the Health General Directorate of the French Social Affairs and Health Ministry. The work done in this study was supported in part by a grant from the European Commission’s 7th Framework Program (contract FP7-HEALTH-2011–282562).

**Notes**
None of the funding agencies participated at any stage in the designing of the study, collection, analysis, interpretation of the data; drafting of the manuscript and the decision to submit the manuscript for publication.

We would like to thank all the patients and their families for their participation. We are also grateful to the support of many clinicians and staff of the hospitals, interviewers, data managers, pathology departments, and primary care clinicians. Gary J. Macfarlane and Tatiana V. Macfarlane partly worked on ARCADE study while at the University of Manchester. We acknowledge the help of Professor Martin Tickle in study conducted in the Manchester center and Professor Phil Sloan who in addition coordinated sample collection and processing for all the UK centers.

**References**


